DA
REGN icon

DCF Advisers’s Regeneron Pharmaceuticals REGN Stock Holding History

DCF Advisers’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,400
Closed -$1.15M – 100
2023
Q3 		$1.15M Buy
+1,400
New +$1.1M 0.63% 38
2022
Q2 		– Sell
-3,000
Closed -$2.1M – 85
2022
Q1 		$2.1M Buy
+3,000
New +$1.9M 0.92% 33

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

DCF Advisers's REGN Position: Q2 2026 in Review

DCF Advisers held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 9,250 shares worth $5.77M. The position accounts for 1.02% of the portfolio, ranked #15.

DCF Advisers first reported a position in REGN in Q4 2019 and has held it in 27 quarters since. The position peaked at $10.9M in Q2 2024. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • DCF Advisers held 9,250 shares of Regeneron Pharmaceuticals worth $5.77M as of Q2 2026.
  • DCF Advisers left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
  • Regeneron Pharmaceuticals made up 1.02% of DCF Advisers's portfolio in Q2 2026, its #15 holding.
  • DCF Advisers first reported a position in Regeneron Pharmaceuticals in Q4 2019 and has held it in 27 quarters since.
  • DCF Advisers's Regeneron Pharmaceuticals position peaked at $10.9M in Q2 2024.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on DCF Advisers's 13F filing for Q2 2026, filed 10 Aug 2026.